List of Excipients in Branded Drug LAMOTRIGINE EXTENDED RELEASE

Generic Drugs Containing LAMOTRIGINE EXTENDED RELEASE

Company	Ingredient	NDC	Excipient
Par Health USA LLC	lamotrigine extended release	49884-561	FERRIC OXIDE RED
Par Health USA LLC	lamotrigine extended release	49884-561	FERRIC OXIDE YELLOW
Par Health USA LLC	lamotrigine extended release	49884-561	HYPROMELLOSES
Par Health USA LLC	lamotrigine extended release	49884-561	METHACRYLIC ACID

What are the Most Frequently-Used Excipients in LAMOTRIGINE EXTENDED RELEASE?

# Of NDCs	Excipient
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE
2	HYPROMELLOSE

Lamotrigine Extended-Release Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Lamotrigine extended-release is a mature small-molecule opportunity in which commercial value depends on bioequivalent release performance, manufacturing efficiency, dose flexibility, and supply reliability. The originator product, Lamictal XR, is no longer protected by meaningful regulatory exclusivity, and generic competition has shifted the market toward cost control and differentiated dosage-form design. The strongest opportunities are high-quality matrix systems, lower-cost excipient platforms, flexible strengths, multiparticulate delivery, and formulation improvements that reduce variability without creating new regulatory complexity.

What is lamotrigine extended-release?

Lamotrigine extended-release is an oral once-daily formulation of lamotrigine used primarily for maintenance treatment of bipolar disorder and adjunctive treatment of partial-onset seizures.

Lamotrigine has a narrow practical tolerability range, complex titration requirements, and clinically important dose-related adverse reactions. Extended release can reduce peak-to-trough fluctuation and simplify administration compared with immediate-release regimens. The product must release lamotrigine consistently over the intended dosing interval while avoiding dose dumping.

Attribute	Lamotrigine extended-release
Active ingredient	Lamotrigine
Originator	GlaxoSmithKline
Originator brand	Lamictal XR
Dosage form	Extended-release tablet
Administration	Once daily
FDA originator approval	2009
Main therapeutic areas	Epilepsy and bipolar disorder
Regulatory category	Small-molecule prescription drug
Generic pathway	ANDA, not biosimilar
Key formulation issue	Controlled matrix dissolution
Main commercial barrier	Demonstrating bioequivalence across the full release profile

The Lamictal XR label identifies multiple strengths, including 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg tablets. Tablets must be swallowed whole and should not be crushed, chewed, or broken because these actions can alter release behavior.[1]

What excipients protect lamotrigine extended-release performance?

The commercial formulation strategy is usually based on a hydrophilic matrix rather than a sophisticated delivery device. The matrix hydrates after ingestion and controls drug diffusion and tablet erosion.

Core excipient functions

Excipient class	Typical candidates	Primary function	Commercial relevance
Hydrophilic polymer	Hypromellose, hydroxypropyl methylcellulose	Controls hydration, gel formation, diffusion, and erosion	Central release-controlling material
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Provides tablet mass and compressibility	Important for cost and tablet size
Binder	Povidone, copovidone, pregelatinized starch	Improves granule and tablet strength	Controls robustness during scale-up
Glidant	Colloidal silicon dioxide	Improves powder flow	Supports content uniformity and production speed
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling friction	Excess can slow dissolution
Anti-adherent	Talc	Reduces sticking and picking	Useful for high-force compression
Film coat	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Identification, swallowability, protection	Supports strength differentiation
Pore former or release modifier	Polyethylene glycol, low-viscosity polymer, soluble filler	Adjusts water ingress and release	Enables profile tuning

The most important formulation variable is not the presence of a particular excipient but the interaction between polymer viscosity, polymer loading, tablet geometry, drug loading, compression force, and dissolution conditions.

How should an excipient platform be designed for lamotrigine ER?

A practical platform should use a robust hydrophilic matrix with a limited number of excipients and a formulation space that supports all marketed strengths.

1. Use a scalable matrix architecture

Hypromellose is the leading starting point because it is widely qualified, available from multiple suppliers, and accepted in oral modified-release products. A combination of high- and low-viscosity grades can provide more control than a single polymer grade.

A high-viscosity polymer can slow release but may increase tablet size, granulation difficulty, and sensitivity to compression. A lower-viscosity grade may improve manufacturability but can produce excessive early release. A dual-grade system allows the developer to tune initial release and terminal erosion independently.

2. Control low-dose content uniformity

The 25 mg strength creates a different technical problem from the 200 mg to 300 mg strengths. At low drug loading, lamotrigine distribution during blending and granulation becomes more important. Segregation risk can increase when particle-size and density differences exist between lamotrigine and excipients.

Commercially useful controls include:

• Narrow particle-size distributions.
• Geometric dilution or ordered mixing.
• Granulation to reduce density differences.
• Low-shear blending after lubrication.
• In-process blend uniformity testing.
• Strength-specific or proportional-composition formulations.

A platform that uses the same qualitative excipient composition across strengths can reduce regulatory and manufacturing complexity, but proportional scaling may not preserve the same dissolution profile. The formulation should be evaluated by strength rather than assumed to be compositionally scalable.

3. Manage lubrication carefully

Magnesium stearate can reduce tablet tensile strength and slow water penetration when overmixed or used at excessive concentrations. Sodium stearyl fumarate can provide a different balance between lubrication and dissolution but may require process re-optimization.

For lamotrigine ER, lubrication time and shear should be treated as critical process parameters. A formulation that passes dissolution at laboratory scale can shift materially during commercial blending if the lubricant distribution changes.

4. Build alcohol-robust dissolution

Modified-release products are evaluated for the possibility of accelerated release in the presence of alcohol. The matrix should be tested in hydroalcoholic media across relevant concentrations and exposure times. Polymer selection, compression force, and tablet porosity can affect alcohol sensitivity.

An alcohol-robust matrix creates a potential product-quality advantage, although the advantage may be difficult to protect unless it is supported by a narrow formulation claim, comparative dissolution data, or a manufacturing process claim.

What formulations are protected by Lamictal XR and generic products?

Lamictal XR is associated with a matrix tablet approach in which excipients regulate lamotrigine release. Generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug under FDA requirements.

The relevant protection has historically included product, formulation, and method-of-use rights associated with lamotrigine and extended-release delivery. The original compound patents for lamotrigine expired years ago. FDA regulatory exclusivity associated with the 2009 Lamictal XR approval also expired long ago. The current competitive question is therefore not basic compound exclusivity but whether any enforceable formulation, process, or method-of-use patent remains relevant to a specific product or market.

Protection category	Current commercial assessment
Lamotrigine compound patent	Expired
Original immediate-release product protection	Expired
Lamictal XR FDA exclusivity	Expired
Extended-release formulation claims	Must be checked against current U.S. patent and litigation records
Method-of-use patents	Potentially relevant but generally limited by statutory scope and claim validity
Generic entry	Established through ANDA approvals
Biosimilar risk	Not applicable because lamotrigine is a chemically synthesized small molecule

The FDA Orange Book is the controlling source for current patent listings tied to the reference product. Patent records can change through delisting, expiration, litigation, or settlement, so a commercial diligence review should use the current NDA 022115 entry rather than historical patent summaries.[2]

When does lamotrigine extended-release lose exclusivity?

Lamotrigine extended-release lost meaningful market exclusivity years ago.

Milestone	Timing
Lamictal XR FDA approval	2009
Three-year regulatory exclusivity associated with a new dosage form	Expired by approximately 2012
Compound patent exclusivity	Expired before the extended-release launch
Generic development window	Open for several years
Current market structure	Generic and multisource competition

The practical consequence is that a new entrant cannot rely on orphan-drug, new-chemical-entity, or active-ingredient exclusivity. Any differentiation must come from quality, economics, supply, delivery, or a separately approved product concept.

Which companies are challenging or competing with Lamictal XR?

The competitive field includes generic manufacturers that have received or pursued ANDA approvals for lamotrigine extended-release tablets. The relevant competitive set can include large generic manufacturers, regional suppliers, and vertically integrated API producers.

Public FDA records identify approved generic products, but commercial participation can differ from approval status because of supply interruptions, authorized-generic arrangements, discontinued presentations, and limited distribution.

The principal competitive dimensions are:

1. Price and payer contracting.
2. Availability of all clinically relevant strengths.
3. Consistent supply of 25 mg and 300 mg tablets.
4. Manufacturing reliability.
5. Packaging and medication-error controls.
6. Ability to maintain dissolution performance after scale-up.
7. API cost and supplier redundancy.

A company with approval only for high-volume strengths may have lower development costs but weaker formulary positioning if pharmacies require a complete titration range.

What Paragraph IV and litigation risks exist?

Paragraph IV risk is materially lower than it was during the initial generic-entry period because the principal regulatory and compound exclusivities have expired. A new ANDA filer could still make a Paragraph IV certification against any unexpired, Orange Book-listed patent. The relevant dispute would likely focus on formulation, release characteristics, manufacturing methods, or a limited method of treatment.

Risk area	Assessment
Compound patent challenge	No longer a central barrier
Extended-release formulation patent	Requires current Orange Book and patent-status review
Paragraph IV notice	Possible if an unexpired listed patent remains
ANDA litigation	Product-specific and dependent on listed patents
Settlement risk	Lower than during early generic entry, but cannot be excluded without current docket review
Launch-at-risk exposure	Primarily tied to any live formulation or process patent

There is no biosimilar litigation pathway because lamotrigine is not a biologic. Litigation risk is instead governed by the Hatch-Waxman framework.

What commercial opportunities exist for lamotrigine ER excipients?

Lower-cost matrix systems

The clearest opportunity is a multi-supplier excipient platform that matches the reference dissolution profile at lower total cost. HPMC suppliers, co-processed diluents, and alternative lubricants can compete on supply assurance, batch consistency, and global regulatory documentation.

Co-processed excipients

Co-processed microcrystalline cellulose, lactose, or mannitol systems may improve flow, compressibility, and low-dose uniformity. A platform that reduces granulation steps can lower equipment requirements and cycle time.

Direct compression

Direct compression can reduce solvent handling and drying costs. Its feasibility depends on lamotrigine particle properties and the ability to maintain content uniformity across low-dose strengths. Direct compression is commercially attractive but may have a narrower process window than wet granulation.

Multiparticulate products

Pellet- or bead-based capsules could provide more consistent gastrointestinal distribution and allow release control through polymer coatings. This strategy may support a differentiated product but usually increases manufacturing cost, equipment requirements, and regulatory development burden.

Orally disintegrating or sprinkle products

These may improve administration for patients with swallowing difficulty. The challenge is preventing premature release while preserving a once-daily profile. Such products would require a new formulation and likely a separate regulatory strategy.

Pediatric and titration-focused presentations

Lamotrigine treatment requires gradual dose escalation. Smaller strengths, flexible dosing packs, and presentation designs that reduce medication errors can create commercial value even without strong patent protection. Any tablet modification must preserve the prohibition against crushing or breaking where release performance depends on tablet integrity.

How does lamotrigine ER compare with immediate-release lamotrigine?

Factor	Extended-release	Immediate-release
Dosing frequency	Typically once daily	Often twice daily
Peak-to-trough fluctuation	Designed to reduce fluctuation	Generally higher
Formulation complexity	Higher	Lower
Excipients	Release-controlling matrix required	Conventional tablet excipients
Generic competition	Established	Extensive
Manufacturing cost	Higher	Lower
Differentiation potential	Release profile and adherence	Price, strength, and supply
Regulatory burden	Dissolution and bioequivalence are more demanding	Simpler release testing

Extended-release has a better technical differentiation opportunity, but immediate-release products have a lower cost base and broader generic manufacturing experience. A commercial program should not assume that a clinically useful once-daily profile automatically produces pricing power.

What FDA regulatory requirements apply?

FDA approval requires pharmaceutical equivalence, bioequivalence, stability, manufacturing controls, and comparative dissolution. The product must demonstrate that its release profile is sufficiently comparable to the reference listed drug under the applicable ANDA pathway.

Key development work includes:

• Comparative dissolution across multiple pH conditions.
• Fed and fasting bioequivalence studies where required.
• Dose proportionality or strength-bracketing justification.
• Alcohol-dose-dumping evaluation.
• Stability under ICH conditions.
• Tablet robustness after handling.
• Content uniformity for low-dose strengths.
• Evaluation of API particle-size and polymorph attributes.
• Process validation at commercial scale.

FDA guidance for orally administered modified-release products emphasizes the relationship between in vitro release and in vivo performance. A formulation with a narrow dissolution window may require more extensive process control than a conventional immediate-release tablet.[3]

How strong is the patent estate for lamotrigine extended-release?

The patent estate is commercially weaker than it was during the original Lamictal XR launch because compound and regulatory exclusivities have expired and generic products are available. Any remaining value is likely to be concentrated in narrow formulation or process claims rather than broad lamotrigine protection.

Patent-estate factor	Commercial strength
Broad active-ingredient protection	Low
Regulatory exclusivity	None of practical relevance
Reference-product market presence	Reduced by generic competition
Formulation patents	Potentially relevant but claim-specific
Process patents	Can create manufacturing barriers if technically narrow
Trade secrets	Relevant for scale-up, coating, blending, and control strategy
Freedom-to-operate risk	Moderate during product design; lower after current-record review

Trade secrets may be more commercially important than patents for excipient ratio, granulation endpoint, compression profile, coating conditions, and dissolution control. Those advantages are difficult for competitors to copy precisely but are also difficult to monetize through premium pricing in a multisource generic market.

What generic launch scenarios exist?

Low-cost multisource launch

A manufacturer launches standard-strength tablets using a conventional HPMC matrix and competes through price. This is the most likely strategy but offers limited margin protection.

Full-strength portfolio launch

A supplier commercializes the complete 25 mg through 300 mg range. This improves pharmacy and payer utility, supports titration, and reduces dependence on one high-volume strength.

Supply-reliability strategy

A manufacturer differentiates through dual API sourcing, redundant excipient suppliers, and validated alternate manufacturing sites. This can support contracts with wholesalers and institutional buyers.

Formulation-differentiated launch

A new dosage form, sprinkle product, or orally disintegrating product targets adherence or swallowing limitations. The development cost and regulatory burden are higher, but the product may have greater lifecycle value.

What geographic opportunities exist?

The United States is a mature ANDA market. Commercial opportunities may be stronger in jurisdictions where once-daily lamotrigine is underpenetrated, generic availability is inconsistent, or local manufacturing incentives apply.

Potential regional strategies include:

• U.S. private-label and contract manufacturing.
• European generic substitution markets.
• Emerging markets with limited access to extended-release presentations.
• Government tenders emphasizing continuity of supply.
• Regional licensing of dossier rights.
• Dual sourcing for markets affected by API or excipient disruptions.

The primary geographic barrier is regulatory duplication. Modified-release products may require country-specific bioequivalence expectations, dissolution methods, labeling, and postapproval change management.

Key Takeaways

• Lamotrigine extended-release is a mature generic opportunity, not a compound-exclusivity opportunity.
• Hypromellose-based matrix systems are the most practical excipient platform.
• The highest technical risks are low-dose content uniformity, scale-up dissolution drift, lubrication effects, and alcohol-related dose dumping.
• Complete strength coverage from 25 mg through 300 mg has commercial value because lamotrigine requires titration.
• Co-processed excipients and direct compression can reduce manufacturing cost, but they require strong uniformity controls.
• Patent value is likely concentrated in narrow formulation and process claims; the current FDA Orange Book record and patent docket control the final assessment.
• Biosimilar risk does not apply. Generic and authorized-generic competition are the relevant threats.
• The best commercial opportunities are supply reliability, lower-cost matrix manufacturing, flexible strengths, and differentiated administration formats.

FAQs

Is hypromellose the best excipient for lamotrigine extended-release?

Hypromellose is the strongest initial candidate because it is established in modified-release tablets, has broad supplier availability, and offers adjustable viscosity grades. The optimal grade and loading must be determined through comparative dissolution and scale-up studies.

Can lamotrigine extended-release tablets use direct compression?

Yes, direct compression is possible if powder flow, compressibility, segregation control, and low-dose uniformity are adequate. Wet granulation may provide a wider process window for the 25 mg strength.

Are there biosimilars for lamotrigine extended-release?

No. Lamotrigine is a chemically synthesized small molecule. Competing products are generics approved through the ANDA pathway.

Can an excipient supplier patent a lamotrigine extended-release formulation?

Potentially. Patentability may exist for a novel excipient combination, defined dissolution profile, manufacturing process, or alcohol-resistant matrix. Broad claims covering conventional HPMC matrices are more difficult to sustain.

Does a new lamotrigine ER formulation qualify for new drug exclusivity?

A materially new formulation may qualify for regulatory protection only if it satisfies applicable FDA requirements and is approved under the relevant pathway. Existing generic approval does not by itself create new exclusivity for conventional excipient substitution.

References

1. GlaxoSmithKline. (2009). Lamictal XR (lamotrigine) extended-release tablets prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (1997). SUPAC-MR: Modified release solid oral dosage forms scale-up and postapproval changes. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2009). Lamictal XR approval package and labeling. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Center for Drug Evaluation and Research.